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In a previous vaccination study in cats, the authors reported on accelerated feline
immunodeficiency virus (FIV) replication upon challenge in animals vaccinated with a candidate
envelope subunit vaccine. Plasma transfer studies as well as antibody profiles in vaccinated cats
indicated a causative role for antibodies directed against the hypervariable regions HV3, HV4
and HV5 (HV3–5) of the envelope glycoprotein. The present study was designed to investigate
further the contribution of antibodies in envelope vaccine-induced acceleration of FIV infection.
To this end, regions HV3–5 of the envelope glycoprotein were deleted from the original vaccine,
thus addressing the contributing role of antibodies directed against these hypervariable regions.
Interestingly, this approach did not prevent acceleration of challenge infection. Analysis of the
antibody responses in the respective groups suggested that removal of HV3–5 redirected the
humoral immune response towards other regions of the envelope glycoprotein, indicating
that these regions can also induce antibodies that accelerate virus replication.
INTRODUCTION
Since the identification of feline immunodeficiency virus
(FIV) in 1986 (Pedersen et al., 1987), several candidate
FIV vaccines have been developed and evaluated (Elyar
et al., 1997; Uhl et al., 2002). The development of a
successful FIV vaccine would not only be of veterinary
interest, but could also provide insight into correlates of
protective immunity in lentivirus infections. It has been
demonstrated that infections with the lentiviruses FIV and
human immunodeficiency virus type 1 (HIV-1) share
biological and clinical characteristics and exhibit a similar
immunopathogenesis, which makes FIV infection of cats
a valuable animal model for AIDS in a natural host
(Bendinelli et al., 1995; Willett et al., 1997a).
The most promising results with candidate vaccines have
been obtained using classical approaches such as inactivated
whole virus and infected cell vaccines (Yamamoto et al.,
1991, 1993; Matteucci et al., 1999, 2000; Pu et al., 2001;
Finerty et al., 2001). However, from these studies it was
not clear what the immune correlates of protection were.
It has been reported that protection correlated with the
presence of virus-neutralizing antibodies on the day of
challenge (Yamamoto et al., 1991, 1993), but vaccine-
induced protection has also been observed in the absence of
virus-neutralizing antibodies (Matteucci et al., 1996).
Candidate FIV subunit vaccines tested to date have failed
to induce protective immunity. The majority of these
vaccines were based on the use of the FIV envelope glyco-
protein (gp130). Vaccines consisted of recombinant bacterial
proteins (Siebelink et al., 1995c; Lutz et al., 1995; Verschoor
et al., 1996; Leutenegger et al., 1998), recombinant baculo-
virus proteins (Lutz et al., 1995; Leutenegger et al., 1998),
recombinant vaccinia virus protein (Siebelink et al., 1995c;
Huisman et al., 1998), peptides representing parts of the
envelope protein (Lombardi et al., 1994; Finerty et al., 2000,
2001; Flynn et al., 1995) or recombinant vectors expressing
the envelope protein or parts thereof (Gonin et al., 1995;
Tijhaar et al., 1997). Recently, partial protection was reported
using an envelope-encoding DNA vaccine co-injected with an
IL12 expression plasmid (Boretti et al., 2000; Leutenegger
et al., 2000).
In contrast, acceleration rather than reduction of FIV repli-
cation was observed upon challenge of vaccinated cats in a
number of studies (Hosie et al., 1992; Lombardi et al., 1994;
Siebelink et al., 1995c; Richardson et al., 1997, 2002; Karlas
et al., 1999; Giannecchini et al., 2002). This phenomenon is
characterized by an accelerated viraemia and sometimes
increased virus loads in FIV-vaccinated animals compared
with mock-vaccinated animals. The accelerated virus repli-
cation correlated with the presence of envelope-specific
antibodies at the time of challenge in some studies
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(Lombardi et al., 1994; Siebelink et al., 1995c; Karlas et al.,
1999; Giannecchini et al., 2002), but not in others (Hosie
et al., 1992; Richardson et al., 1997, 2002). Hence, the
mechanism underlying this enhancement phenomenon has
not been fully elucidated. Transfer studies using plasma of
vaccinated animals strongly suggested the involvement of
plasma-associated factors, like virus-specific antibodies or
cytokines (Siebelink et al., 1995c). Moreover, the accelerated
viraemia also correlated with the presence of antibodies
specific for the hypervariable regions HV3, HV4 and HV5
(Siebelink et al., 1995c). We showed that cat antisera raised
against FIV molecular clone 19k1 neutralized this virus
but enhanced the replication of a closely related molecular
FIV clone, 19k32, in vitro (Siebelink et al., 1992; unpublished
results). Since these two clones differ in their envelope
amino acid sequence at only four positions, all located in
regions HV4 and HV5, we hypothesized that antibody
responses against these regions are involved in antibody-
mediated acceleration of infection.
Here, we report on the in vivo evaluation of a recombinant
FIV envelope glycoprotein candidate vaccine from which
the regions HV3–5 were deleted. The results show that
antibodies directed against HV3–5 are not solely responsible
for vaccine-induced acceleration of infection.
METHODS
Cells and viruses. Peripheral blood mononuclear cells (PBMCs)
were isolated from blood samples using Lymphoprep (Axis-Shield),
aliquoted and stored at 2135 uC. Assays were performed retrospec-
tively to guarantee identical experimental conditions for all samples.
After thawing, PBMCs were allowed to recover overnight in RPMI
(Cambrex Bioscience) supplemented with penicillin (100 IU ml21),
streptomycin (100 mg ml21), L-glutamine (2 mM), b-mercaptoethanol
(261025 M) and 10% foetal bovine serum (Greiner Bio-One)
(R10F medium). The following day, the cells were washed and sub-
sequently cultured in R10F medium supplemented with concanavalin
A (4 mg ml21; Sigma-Aldrich) and recombinant human interleukin 2
(rhuIL2, 200 IU ml21; Red Swan Pharma Logistics). After 3 days,
cells were washed and cultured in R10F medium plus rhuIL2
(200 IU ml21).
Crandel feline kidney (CrFK) cells originated from an FIV-susceptible
clone, CrFK 1D10, originally provided by N. Pedersen (Yamamoto
et al., 1988) and were cultured in Dulbecco’s modified Eagle’s medium
(Cambrex Bioscience) supplemented with penicillin (100 IU ml21),
streptomycin (100 mg ml21), L-glutamine (2 mM), b-mercaptoethanol
(261025 M) and 10% foetal bovine serum (D10F medium).
FIV AM19 was used as the challenge virus, as described previously
(Siebelink et al., 1995c). This virus was originally isolated from PBMCs
of a naturally infected cat, and an in vitro-grown virus stock was
subsequently titrated in vivo (Siebelink et al., 1995c).
FIV AM6c was used in the CrFK-based virus neutralization assay
(see below). This virus was also isolated from a naturally infected cat
and subsequently adapted to replicate on CrFK 1D10 cells (Siebelink
et al., 1995b). The env sequence homology of FIV AM6c and the
molecular clone FIV 19k1 is 94?8%.
Vaccines: recombinant vaccinia virus (rVV) constructs. The
candidate vaccines used in this study were either identical to or
derivatives of the vGR657x15 vaccine described previously
(Rimmelzwaan et al., 1994), which has been shown to be responsible
for vaccine-induced enhancement of challenge infection (Siebelink
et al., 1995c). vGR657x15 consists of a VV-expressed, lentil lectin–
Sepharose column-purified FIV envelope protein. The cleavage site
between the surface and transmembrane protein has been deleted
through site-directed mutagenesis to facilitate incorporation into
immune-stimulating complexes (iscoms) (Rimmelzwaan et al., 1994).
For clarity, this vaccine is referred to as FIV-Env-iscom.
A schematic representation of the regions deleted from the DEnv
construct is provided in Fig. 1. To generate the FIV-DEnv vaccines,
the envelope of FIV 19k1 was amplified using two different primer
sets [DENV1 (59-GGGTACCTGGAATAACAC-39) with DENV2
(59-GGTCGACCCACCATCCACATTTTGG-39, SalI), and DENV3
(59-GGTCGACGGCATCTTAAGAAATTGG-39) with DENV4 (59-
CCTACCCAATCTTCCCAC-39, SalI) (restriction sites underlined)]
generating two fragments, 59DEnv and 39DEnv. These fragments
were linked by the introduced SalI site. This resulted in an envelope
sequence missing aa 358–567 (based on the envelope sequence of FIV
19k1; GenBank accession no. M73964), which constitute HV3–5.
Internal KpnI sites were used to exchange DEnv with the original
envelope sequence in pGR657x15, the plasmid originally used to
generate vGR657x15 (Rimmelzwaan et al., 1994). Subsequent genera-
tion of rVV-GR657x15-DEnv, production, isolation, purification and
incorporation into iscoms was done as described for rVV-GR657x15
(Rimmelzwaan et al., 1994). The obtained vaccine is referred to as
FIV-DEnv-iscom.
Polyclonal rabbit sera raised against bacterial fusion proteins were
used to characterize and identify the produced envelope proteins;
serum Ra2194 recognized HV4 and serum Ra2279 recognized epitopes
located between HV2 and HV3 (de Ronde et al., 1994).
Animals, vaccination and challenge. The specific-pathogen-free
(SPF) cats used in this study were obtained from Harlan (Horst).
An external ethical committee approved the protocol used in this
study. Twelve animals were randomly distributed into groups: group
1 (n=3) was vaccinated with the original FIV-Env-iscom prepara-
tion; group 2 (n=4) was vaccinated with the FIV-DEnv-iscom pre-
paration; group 3 (n=5) received PBS (non-vaccinated controls).
Originally, group 1 consisted of four animals; however, one animal
died during the vaccination scheme due to reasons not related to the
experimental set-up of this study. Cats were inoculated with the
respective vaccines at weeks 0, 6 and 10, identical to the previous
study (Siebelink et al., 1995c). Each vaccine dose contained 1?5 mg
envelope protein. Animals were challenged intramuscularly with 20
CID50 FIV AM19 2 weeks after the last vaccination. PBMCs and
plasma samples were obtained before and 1, 2, 3, 4, 6 and 8 weeks
post-challenge.
Fig. 1. Full-length FIV precursor envelope
glycoprotein. The regions that were deleted
to generate the DEnv glycoprotein are
dashed. SU, surface subunit; TM, trans-
membrane subunit; HV, hypervariable region.
The arrow indicates the highly hydrophobic
leader sequence.
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Virus neutralization assay. A virus neutralization assay based on
the inhibition of FIV AM6c infection of CrFK cells was performed
as described previously (Siebelink et al., 1995c).
Env ELISA
Cloning into prokaryotic expression vectors. A modified version
of the pThio plasmid (Invitrogen) was used to generate expression
vectors containing FIV 19k1 (Siebelink et al., 1992) env sequences.
The modifications were introduced for detection and purification
purposes. Using primers ThioHisfor (59-GCGTCTAGAATCCCTAA-
CCCTCTCC-39, XbaI) and ThioHisback (59-CGCGCTGCAGTCAA-
TGGTGATGGTGATGATG-39, PstI) and pMT/V5-His (Invitrogen)
as a template, the V5 epitope and the hexahistidine (66His)-tag
were amplified, after which the PCR product was cloned into XbaI/
PstI-digested pThio. The obtained expression vector was named
pThio/V5-His. Expression products from this expression vector were
thioredoxin fusion proteins, containing a C-terminal V5 epitope for
detection purposes and a 66His-tag for purification.
Using Pwo Taq polymerase (Stratagene), env sequences were directly
amplified from a 39-19k1 pUC19 subclone (Siebelink et al., 1992). For
the Env-SU (surface subunit region) construct, the primers 59-CG-
GGATCCGACCCATTACAAATCCCACTG-39 (BamHI) and 59-CG-
TCTAGATCTTTTTCTTCTAGGTTTATATTC-39 (XbaI) were used.
For the Env-TM (transmembrane region) construct, the primers
59-CGGGATCCGGCATCTTAAGAAATTGGTAT-39 (BamHI) and 59-
CGTCTAGATTGATTACATCCTAATTCTTGC-39 (XbaI) were used.
The obtained amplicons were subsequently digested with BamHI and
XbaI and cloned into BamHI/XbaI-digested pThio/V5-His.
The Env-SU construct incorporated Env 19k1 aa 322–611 (Env19k1,
NCBI nucleotide accession no. M73964), containing HV3, HV4 and
HV5 and flanking regions that were not deleted from the DEnv
constructs. The Env-TM construct incorporated Env 19k1 aa 567–701,
containing the principal immunodominant domain.
The generated plasmids were checked by restriction enzyme analysis
and sequencing.
Expression and purification of bacterial recombinant fusion pro-
teins. For expression of the fusion proteins, plasmid DNA was
transfected into BL21pLysS bacteria (Stratagene). After culturing a
single colony in 10 ml SOB medium [20 g Tryptone Peptone l21
(Difco), 5 g yeast extract l21 (Difco), 0?5 g NaCl l21, 2?5 mM KCl,
10 mM MgCl2, pH 7?0] with 100 mg ampicillin ml
21 for 2 h, the
bacteria were subsequently cultured in 500 ml SOB/ampicillin until
an OD600 of 0?5–0?6 was reached. Expression was induced by adding
IPTG (Roche) to a final concentration of 1 mM. After 4 h of induc-
tion at 20–37 uC, depending on the construct, the bacteria were
pelleted by centrifugation at 900 g for 15 min and immediately used
for purification or frozen overnight at 220 uC.
Subsequently, the pelleted bacteria were solubilized overnight in 5 ml
lysis buffer (6 M guanidine/HCl, 0?1 M NaH2PO4, 0?01 M Tris/HCl
pH 8?0) per 500 ml bacterial culture. The resulting lysate was
centrifuged for 15 min at 10 000 g at 4 uC. The supernatant was then
incubated with ProBond resin (Invitrogen) for 1 h at room tempera-
ture. After stacking and washing of the column material, guanidine/
HCl was replaced with urea by washing the column with 10 ml wash
buffer (8 M urea, 0?1 M NaH2PO4, 0?01 M Tris/HCl pH 6?3). After
an additional washing step with wash buffer (pH 5?9), elution was
carried out with elution buffer (8 M urea, 0?1 M NaH2PO4, 0?01 M
Tris/HCl pH 4?5). Washing and elution steps were carried out at 4 uC.
Purification was checked by SDS-PAGE on 15% polyacrylamide gels
and Western blot analysis using an anti-V5 monoclonal antibody
(Invitrogen). Elution fractions containing the highest concentration of
fusion protein were pooled and used in the ELISA.
ELISA. ELISA plates (96-well; Corning) were coated with 100 ng of
recombinant protein in PBS (Gibco) per well. As a control antigen,
an FIV Orf A–thioredoxin fusion protein was used, expressed and
purified as for the envelope fusion proteins. After blocking with
ELISA buffer consisting of Meddens reagent (Meddens, Woerden,
The Netherlands) supplemented with 0?5% BSA and 0?05% Tween
20, the plasma samples were incubated in a 1 : 100 dilution in ELISA
buffer for 1 h at 37 uC. Mouse anti-cat IgG (1 : 300; Serotec) was
used as a first conjugate, followed by HRP-conjugated rabbit anti-
mouse IgG (1 : 1000; DAKO). 3,39,5,59-Tetramethylbenzidine (TMB)
in TMB diluent (Meddens) was used as substrate. The reaction was
stopped after 5 min by adding an equal volume of 2 M H2SO4.
Background values against the Orf A fusion protein were subtracted
from the Env-SU and Env-TM values to obtain specific OD450
values.
Virus loads
Plasma virus load. Plasma virus loads were determined with a real-
time PCR (TaqMan) assay according to a protocol described pre-
viously (Klein et al., 1999; Leutenegger et al., 1999) on an ABI prism
7700 Sequence Detection System (Applied Biosystems). Primers and
probe sequences (Klein et al., 1999; Leutenegger et al., 1999) were
adapted to the FIV 19k1 sequence when different. Primer concentra-
tions of 15 pmol (300 mM) and 30 pmol (600 mM) were found to be
optimal for the forward and reverse primers, respectively. The opti-
mal probe concentration was 10 pmol (200 mM). The real-time PCR
was performed using the EZ-core kit (Applied Biosystems). The RT-
PCR cycling programme was initiated with a 2 min 50 uC uracyl
amperase step, followed by a 30 min 60 uC RT step, 5 min denatura-
tion at 95 uC and 45 cycles of a two-step PCR consisting of 20 s at
95 uC and 1 min at 62 uC. Data were collected during the annealing
step (62 uC). A diluted 19k1 virus stock was used in each run to
obtain a standard curve. Feline plasma (190 ml) was spiked with a
known phocine distemper virus stock that was used as an internal
control to control for efficiency of RNA isolation (unpublished
data). RNA was extracted from plasma (total 200 ml input) and con-
centrated fourfold (50 ml output) with a Magnapure LC Isolation
Station (Roche), using the Magna Pure LC Total Nucleic Acid
Isolation kit (Roche).
Cell-associated virus load. Provirus loads or cell-associated virus
loads were determined using a slightly modified infectious centre
test, described previously (Siebelink et al., 1995c). Briefly, threefold
serially diluted PBMC samples obtained after challenge infection
were co-cultured in 96-well U-bottom plates (Greiner Bio-One)
with a concanavalin A- and rhuIL2-stimulated mixture of PBMCs
from two SPF cats in 10 wells. Culture medium containing rhuIL2
was added weekly to maintain the cultures. After 4 weeks, the
culture supernatants were analysed for the presence of FIV antigen
by ELISA (Siebelink et al., 1990). The number of infected cells in the
PBMCs was calculated from the results of the ELISA by assuming
that one infected cell gave rise to FIV antigen production after co-
cultivation with the stimulated PBMCs, when one or more cultures
tested in the 10 wells were negative for FIV antigen.
Statistical analyses. For statistical analysis of the data between
two groups, the Mann–Whitney test was used.
RESULTS
Generation of FIV-DEnv-iscom
BHK cells were infected in parallel with rVV-GR657x15-
Env or rVV-GR657x15-DEnv. Two days post-infection,
crude cell-lysates were prepared and after purification of
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the FIV glycoproteins, iscoms were prepared and quality
controlled as described previously (Rimmelzwaan et al.,
1994). In addition, iscom preparations were analysed by
SDS-PAGE followed by Western blotting. As shown in
Fig. 2(a), the FIV-Env-iscom preparation contained an
envelope protein with a molecular mass of 130 kDa,
confirming the expression of the non-cleaved 688 aa FIV
envelope glycoprotein by rVV-vGR657x15, as reported
previously (Rimmelzwaan et al., 1994). Deletion of HV3–5
resulted in expression of a protein with a molecular mass
of approximately 60 kDa. Western blot analysis using
polyclonal antisera against HV2–3- and HV4-specific enve-
lope regions confirmed the successful deletion of HV3–5.
As can be seen in Fig. 2(a), the a-HV2–3 serum clearly
identified the expression of both the intact envelope and
the envelope glycoprotein from which HV3–5 were deleted,
while with the a-HV4 serum (Fig. 2b), the intact envelope
glycoprotein was detected but not the envelope glyco-
protein from which HV3–5 had been deleted.
Vaccine-induced immune responses
Virus-neutralizing antibodies. Cats vaccinated with FIV-
Env-iscoms developed virus-neutralizing antibody (VNA)
titres against FIV infection of CrFK cells with titres rang-
ing from 160 to 5120 on the day of challenge (Table 1).
The titres were comparable to those measured on the day
of challenge in the study by Siebelink et al. (1995c), in
which the same candidate vaccine was used. In plasma
samples of control cats and those vaccinated with FIV-
DEnv-iscoms, VNAs (titres¢20) were not demonstrated
on the day of challenge.
Envelope-specific antibodies. To study the immuno-
genicity of the FIV-DEnv-iscoms, plasma samples of vacci-
nated cats were tested in an ELISA for the detection of
envelope protein-specific antibodies. As shown in Fig. 3(a),
all cats vaccinated with the FIV-Env-iscoms had developed
significant antibody responses against Env-SU by 2 weeks
after the last vaccination (P=0?025, compared with con-
trol animals). Two cats vaccinated with FIV-DEnv-iscoms
also mounted an antibody response against Env-SU.
The same two animals in group 2 also mounted a signifi-
cant Env-TM-specific antibody response. In contrast, cats
from the control group 3 and group 1 failed to develop an
antibody response against the TM part of the envelope
glycoprotein.
Outcome of challenge infection
Plasma virus loads. Plasma virus load kinetics in the res-
pective groups of vaccinated cats were similar, irrespective
Fig. 2. Western blot analysis of candidate vaccine preparations
using polyclonal rabbit serum directed against the region
between HV2 and HV3 (a) and against HV4 (b) as the primary
antibody. Lane 1, FIV-Env-iscom; lane 2, FIV-DEnv-iscom. Mole-
cular mass markers are indicated on the right of each panel.
Table 1. Virus neutralizing antibody titres
Group Vaccine Cat no. Virus neutralization titre (1/x) (weeks post-challenge)
0 1 2 3 4 6 8
1 FIV-Env 1 160 160 640 5 120 10 240 2 560 640
2 5 120 2 560 1 280 5 120 >40 960 10 240 5 120
3 320 80 160 80 640 640 1 280
2 FIV-DEnv 4 <20 <20 20 80 2 560 1 280 5 120
5 <20 <20 20 40 40 10 240 5 120
6 <20 <20 <20 40 1 280 2 560 1 280
7 <20 <20 <20 40 160 10 240 10 240
3 PBS 8 <20 <20 <20 <20 <20 160 2 560
9 <20 <20 <20 <20 40 2 560 10 240
10 <20 <20 <20 <20 <20 80 40 960
11 <20 <20 <20 <20 <20 320 5 120
12 <20 <20 <20 <20 <20 2 560 ND
ND, Not determined.
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of the vaccine used (Env vs DEnv, Fig. 4a). At two weeks
post-challenge, plasma virus loads were significantly higher
in group 2 (median 22 400 copies ml21) compared with
control group 3 (median 0, P=0?041). Group 1 (FIV-Env-
iscom, median 26 000 copies ml21) also exhibited a trend
towards higher virus loads in circulation (P=0?167). Peak
virus loads ranged from 60 000 to 4 600 000 copies ml21,
with no significant differences between groups. However,
envelope protein-vaccinated animals reached peak plasma
virus loads 1–3 weeks earlier than animals in the control
group. These plasma virus load kinetics suggested vaccine-
induced acceleration of infection in envelope-vaccinated
animals.
Cell-associated virus loads. Accelerated virus replication
upon challenge infection was more pronounced when cell-
associated virus loads were analysed in the respective groups
(Fig. 4b): animals vaccinated with the respective candidate
envelope vaccines exhibited significantly higher numbers of
FIV-infected cells at 2 weeks post-challenge [median 30 and
42?5 infected cells (106 PBMCs)21, respectively], compared
with control animals in which no FIV-infected cells were
found at this time (P<0?05). Peak provirus loads ranged
from 25 to >1000 infected cells (106 PBMCs)21, with
no significant differences between groups. FIV envelope-
vaccinated animals showed peak provirus levels 2–4 weeks
earlier than animals in the control group.
Post-challenge virus-neutralizing antibody
kinetics
Upon infection, all cats vaccinated with FIV-Env-iscoms
developed an anamnestic antibody response. Virus-
neutralizing antibody titres ¢5120 were measured in
individual cats from 3 weeks post-challenge onward
(Table 1). The FIV-DEnv vaccinated cats (group 2)
exhibited faster VNA titre kinetics compared with the
Fig. 3. Env-ELISA. Plasma samples obtained on the day of
challenge were diluted 1 : 100 and tested by ELISA against
100 ng coated recombinant bacterial fusion protein encoding
either the surface (a) or the transmembrane (b) subunit of the
envelope protein. Group 1, FIV-Env-iscom; group 2, FIV-DEnv-
iscom; group 3, PBS. Symbols represent individual cats.
Fig. 4. Virus loads. Plasma and PBMCs isolated after chal-
lenge infection were quantitatively analysed for the presence of
FIV particles (a) and provirus (b). $, Group 1, m, group 2, &,
group 3. An asterisk denotes a significant difference compared
with control group, P<0?05.
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mock-vaccinated cats (group 3), as two out of four cats
developed VNA titres from 2 weeks post-challenge onward
(all cats were positive at 3 weeks post-challenge), while
most mock-vaccinated cats did not develop VNA titres
until week 6 post-challenge.
DISCUSSION
In the present study it was shown that antibodies directed
against FIV envelope regions HV3–5 are not solely responsi-
ble for vaccine-induced acceleration of challenge infection.
We have previously shown that vaccination with an enve-
lope protein iscom preparation predisposed cats to acceler-
ated viraemia upon challenge infection with FIV (Siebelink
et al., 1995c). Antibodies directed against the envelope
protein were considered to be involved in this phenomenon,
since naı¨ve cats exhibited an accelerated viraemia upon
passive transfer with plasma obtained from the vaccinated
animals and subsequent virus challenge. The accelerated
virus replication correlated with the presence of virus-
neutralizing and HV3–5-specific serum antibodies on the
day of challenge (Siebelink et al., 1995c). In addition,
vaccination of cats with a peptide containing the V3 region
of the FIV envelope protein induced enhanced virus repli-
cation, which correlated with accelerated VNA titre kinetics
(Lombardi et al., 1994). To address the role of HV3–
5-specific antibodies in vaccine-induced acceleration of
infection, we vaccinated cats with iscom candidate vaccines
containing either the entire FIV envelope glycoprotein
(Siebelink et al., 1995c) or the envelope glycoprotein from
which regions HV3–5 were deleted (FIV-DEnv-iscom). It
was shown that plasma virus and provirus load kinetics
were similar for both the FIV-Env-iscom and the FIV-DEnv-
iscom vaccinated cats, indicating that antibody responses
against HV3–5 were not solely responsible for FIV envelope
vaccine-induced acceleration of infection. Passive transfer
of post-vaccination plasma and subsequent infection of
naı¨ve cats could provide supportive evidence that the
accelerated virus replication in FIV-DEnv-iscom-vaccinated
cats was antibody mediated, as was demonstrated with
plasma from cats vaccinated with FIV-Env-iscoms
(Siebelink et al., 1995c). Since the virus replication kinetics
in FIV-DEnv-iscom-vaccinated cats was similar to that in
cats vaccinated with FIV-Env-iscoms, we speculate that
in FIV-DEnv-iscom-vaccinated cats the accelerated virus
replication was also mediated by antibodies. In contrast
to the FIV-Env-iscom-vaccinated groups, enhancement of
virus replication was observed in the absence of detectable
VNA titres on the day of challenge in FIV-DEnv-iscom-
vaccinated cats (Table 1). The absence of VNA in these
animals is most likely explained by the absence of the
regions HV3–5 from the vaccine preparation since we
and others have shown that neutralization of FIV infection
in vitro is mainly mediated by antibodies directed against
(conformational) epitopes involving regions HV3 (Lombardi
et al., 1993, 1995) and/or HV4 and HV5 (Siebelink et al.,
1993, 1995a; Verschoor et al., 1995). Although the HV3–5
deletion may have compromised the conformation of the
envelope glycoprotein, the DEnv glycoprotein was still
immunogenic and Env-specific antibodies were detected
by ELISA. Since bacterially expressed proteins were used in
the ELISA, antibodies against remaining conformational
epitopes may have been missed.
Post-challenge serum VNA responses in the FIV-DEnv-
iscom-vaccinated group developed more rapidly than in
the control group. This may have been caused by the
accelerated kinetics of virus replication, by a priming effect
of the FIV-DEnv-iscom vaccine on the induction of VNA
specific for epitopes outside HV3–5, or a combination of
both mechanisms. HIV-1 vaccination studies in guinea
pigs have demonstrated that masking of the envelope V3
region by the introduction of N-linked glycosylation sites
and reduction of the net positive charge resulted in the
induction of antibodies specific for the V1 region and with
a broader neutralizing capacity in vitro than antibodies
induced by the original protein (Garrity et al., 1997).
Furthermore, in an attempt to generate immunogenically
superior HIV-1 envelope proteins, it has been shown that
removal of one or more of the V1, V2 or V3 loops can
result in the exposure of normally obscured, conserved
neutralization epitopes (Sanders et al., 2000). Thus, the
antibody response induced by FIV-DEnv-iscoms may have
been redirected towards regions on the envelope protein
other than HV3–5 and have primed for the induction of
post-challenge antibodies that can neutralize FIV in vitro
but may predispose for accelerated infection in vivo. This
is in agreement with the more efficient induction of
antibodies specific for epitopes present in the TM region
of the envelope glycoprotein observed after vaccination
with FIV-DEnv-iscoms (see Fig. 3b, Env-TM response).
As in HIV-1 neutralization, these epitopes may also be
involved in in vitro virus neutralization of FIV.
It has been suggested that antibodies directed to the
principal immunodominant domain (PID), located in the
extracellular part of the TM region, are involved in
enhancement of HIV-1 infection of cell cultures in vitro
(Robinson et al., 1990). The high similarity between HIV-1
and FIV PID structures (Pancino et al., 1995) suggests that
this region may be involved in the induction of antibodies
mediating enhancement of FIV infection. However, the
observation that immunization of cats with a peptide
containing the FIV PID resulted in reduced virus loads
upon challenge infection compared with control animals
(Richardson et al., 1998) does not support this option.
Collectively, these results point towards major differences
between virus neutralization in vitro and in vivo, and it
should be stressed that data generated in vitro should be
extrapolated cautiously to the in vivo situation. Indeed, the
physiological microenvironment has been shown to have a
major effect on the infectivity of HIV-1 isolates in PBMCs
and monocyte-derived macrophages (Wu et al., 1995).
Considering the outcome of this study, epitope deletion as
an approach to improve the efficacy of candidate lentiviral
vaccines is not likely to result in a successful vaccine.
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Although it has been shown for HIV-1 infection in vitro
that antibody-mediated enhancement by a monoclonal
antibody could be abrogated by mutating the targeted
epitope (Mitchell et al., 1998), this is less likely to occur in
the context of a polyclonal immune response in vivo.
In vitro infection experiments have revealed possible
mechanisms involved in enhancement of HIV-1 infection
besides virus-specific antibodies. For example, it has been
shown that more efficient virus entry was mediated by
components of the complement system and their receptors
(Boyer et al., 1991; Tacnet-Delorme et al., 1999). These
mechanisms may also act in vivo. Since in most studies
cats are challenged shortly (within 2–4 weeks) after the last
booster vaccination, an additional role for other mechan-
isms, such as immune activation, in vaccine-induced
acceleration of infection cannot be excluded (Richardson
et al., 1997, 2002; Karlas et al., 1999). We have attempted
to address the role of immune activation in another group
of cats that was vaccinated with FIV-Env-iscoms by
challenging these animals 12 weeks after the last booster
vaccination instead of 2 weeks. Despite this adjourned
challenge, both provirus and plasma virus load kinetics
developed similar to groups 1 and 2 of the current study
(data not shown). Both virus-neutralizing titres as well as
envelope-specific antibody responses (ELISA) were similar
to those described for the FIV-Env-iscom-vaccinated
animals in the current study. Therefore, it was suspected
that antibodies, not vaccine-induced immune activation,
were at the basis of the observed accelerated virus repli-
cation. However, a control group vaccinated with simian
immunodeficiency virus (SIV)-Env-iscoms and challenged
2 weeks after the last booster vaccination exhibited virus
load kinetics in between those of the PBS controls and the
groups with accelerated virus replication. Since an SIV-
Env-iscom-vaccinated group challenged 12 weeks after the
last booster vaccination was not included, we could not
accurately assess the potential involvement of immune
activation in this set-up and these groups were therefore
not included in this study.
The difference in virus replication kinetics in vaccinated
compared with control cats was more pronounced when
virus loads were tested as the number of infected cells in
the infectious centre test than when plasma loads were
tested by real-time PCR (compare Fig. 4a and b). This
suggests that in the vaccinated cats a more efficient entry
of virus into susceptible cells took place. Recent studies
suggest that the specific activation of lentivirus-specific
CD4+ T cells results in an increased susceptibility to
infection of these cells (Richardson et al., 1997, 2002;
Douek et al., 2002). Accordingly, the induction of FIV-
specific CD4+ T cells by vaccination could have supported
a more efficient infection of these cells upon challenge
infection, possibly through an increased expression of
CXCR4 (Willett et al., 1997b). However, earlier results
showing that a factor responsible for vaccine-induced
enhancement of virus replication could be transferred to
naı¨ve cats by plasma obtained from cats vaccinated with
an FIV-Env-iscom vaccine (Siebelink et al., 1995c) argue
against a role for virus-specific CD4+ T cells as a single
determinant responsible for vaccine-induced enhancement
of virus replication. Still, it cannot be ruled out that multiple
vaccine-induced mechanisms are involved in the observed
accelerated virus replication.
The present study has shown that vaccine-induced enhance-
ment of FIV challenge infection is not exclusively mediated
by antibody responses against epitopes within HV3–5 of
the envelope glycoprotein. Since the envelope iscom
vaccine from which these regions were deleted retained its
property to induce an antibody response that predisposed
for accelerated viraemia upon challenge infection, other
regions of the envelope glycoprotein may be involved in
antibody-mediated acceleration of infection as well. Until
those regions are identified, the use of the envelope glyco-
protein as a candidate subunit vaccine against FIV infection
of cats should be considered with caution.
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